Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors


Цитировать

Полный текст

Аннотация

Cardiotoxicity represents an important acute or chronic adverse event of treatment modalities for childhood cancer. In the last two decades the emergence of novel cancer therapies has aimed to increase unaided or mostly in combination with conventional chemotherapy for the survival rates of pediatric cancer especially for those patients with relapsed and/or refractory disease. The use of emerging targeted therapies in combination with conventional chemotherapy is related to cardiovascular adverse events mostly reported in adults. The aim of our short review was to investigate the cardiotoxic side effects of targeted chemotherapeutic agents as monoclonal antibodies and small molecules in pediatric cancer patients.

Об авторах

Athanasios Bangeas

epartment of 2nd Paediatric, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital

Email: info@benthamscience.net

Athanasios Tragiannidis

Department of 2nd Paediatric, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Steliarova-Foucher, E.; Colombet, M.; Ries, L.A.G.; Moreno, F.; Dolya, A.; Bray, F.; Hesseling, P.; Shin, H.Y.; Stiller, C.A.; Bouzbid, S.; Hamdi-Cherif, M.; Hablas, A.; Chirpaz, E.; Buziba, N.; Chesumbai, G.C.; Manraj, S.S.; Reynders, D.; Wabinga, H.R.; Chokunonga, E.; Moreno, F.; Lima, C.A.; Asturian, L.C.; de Oliveira, J.C.; de Aquino, J.A.P.; Gallagher, S.M.V.; Uribe, C.J.; Bravo, L.E.; Yepez, C.M.C.; Torres, A.G.; Galán, A.Y.H.; Martinez, R.F.C.; Castillo, C.J.C.; Mendoza, A.M.; Cueva, A.P.; Hanchard, B.; Fajardo-Gutiérrez, A.; Zavala Zegarra, D.E.; Barrios, E.; Nikiforuk, C.; Woods, R.; Turner, D.; MacIntyre, M.; Corriveau, A.; Navaneelan, T.; Bertrand, C.; Stuart-Panko, H.; Wilson, R.J.; Kosary, C.; Shen, X.; Brockhouse, J.; Yee, G.A.; Mitchell, T.C.; Snipes, K.; West, D.; Rao, C.; Bolick, S.; Rycroft, R.K.; Mueller, L.; Zheng, Y.; Dosch, K.; Brown, H.; Vargas, A.; Levin, G.M.; Bayakly, R.; Johnson, C.; Shen, T.; Ruppert, L.; Lynch, C.F.; Lai, S.M.; Tucker, T.C.; Wu, X.C.; Schwenn, M.; Stern, K.; Gershman, S.; Copeland, G.; Bushhouse, S.; Rogers, D.B.; Jackson Thompson, J.; Lemons, D.; Frederick, S.; Harris, J.A.; Riddle, B.; Stroup, A.; Wiggins, C.; Schymura, M.J.; Giljahn, L.K.; Sheikh, A.; Schubert, S.; Aldinger, W.; Fulton, J.P.; Whiteside, M.; Nogueira, L.; Sweeney, C.; Johnson, A.; Martin, J.; Farley, S.; Harrelson, D.; Malicki, R.; Espinoza, J.R.; Hernandez, B.Y.; Abulfateh, N.; Wang, N.; Ngan, R.K.C.; Lingegowda, K.B.; Swaminathan, R.; Koyande, S.S.; Silverman, B.; Ozasa, K.; Kanemura, S.; Soda, M.; Miyashiro, I.; Shibata, A.; Nimri, O.; Won, Y.J.; Kim, C.H.; Hong, N.S.; Nam, H.S.; Kweon, S.; Kim, W.C.; Huh, J.S.; Jung, K.W.; Yoo, C.I.; Elbasmy, A.; Laudico, A.V.; Lumague, M.R.; AlMutlag, H.; Buasom, R.; Srisukho, S.; Tanabodee, J.; Wiangnon, S.; Pongnikorn, D.; Sriplung, H.; Dirican, O.; Eser, S.; Le Hoang, M.; Hackl, M.; Zborovskaya, A.; Dimitrova, N.; Valerianova, Z.; Sekerija, M.; Pavlou, P.; Dušek, M.; Mägi, M.; Clavel, J.; Lacour, B.; Guizard, A.V.; Bouvier, V.; Troussard, X.; Woronoff, A.S.; Tretarre, B.; Colonna, M.; Molinié, F.; Bara, S.; Velten, M.; Marrer, E.; Ganry, O.; Grosclaude, P.; Kaatsch, P.; Zeissig, S.R.; Holleczek, B.; Katalinic, A.; Jakab, Z.; Birgisson, H.; Walsh, P.M.; Mangone, L.; Merletti, F.; Magoni, M.; Mangone, L.; Ferretti, S.; Serraino, D.; Spagnoli, G.; Fusco, M.; Michiara, M.; Tumino, R.; Falcini, F.; Sensi, F.; Tisano, F.; Piffer, S.; Stracci, F.; Tagliabue, G.; Smailyte, G.; Agius, D.; Visser, O.; Ursin, G.; Didkowska, J.; Trojanowski, M.; Wojciechowska, U.; Forjaz de Lacerda, G.; Silva, M.A.; Laranja, P.J.; da Costa Miranda, A.; Kaiserova, E.; Primic, Ž.M.; Peris-Bonet, R.; Vicente, R.M.L.; Almar, M.E.; Quirós, G. J.R.; Ramos, M.M.; Errezola Saizar, M.; Alemán Herrera, A.; Díaz, G.J.M.; Marcos-Gragera, R.; Sanchez-Perez, M.J.; Ardanaz, A.E.; Galceran, J.; Klint, A.; Kuehni, C.E.; Bouchardy, C.; Levi, F.; Bordoni, A.; Konzelmann, I.; Rohrmann, S.; Stiller, C.A.; Gavin, A.T.; Brewster, D.H.; Phung, H.; Rushton, S.; Guthridge, S.; Aitken, J.; D'Onise, K.; Venn, A.; Farrugian, H.; Threlfall, T.J.; Laumond, S.; Yen Kai Sun, L.; Hendrix, J.; Ballantine, K.; Colombet, M.; Dolya, A.; Masuyer, E.; Steliarova-Foucher, E. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol., 2017, 18(6), 719-731. doi: 10.1016/S1470-2045(17)30186-9 PMID: 28410997
  2. Sherry, L.M.; Xu, J.; Kochanek, K.D.; Arias, E.; Tejada-Vera, B. Deaths: Final Data for 2018. National Vital Statistics Reports, 2018, 69(13)
  3. Howlader, N.; Noone, A.M.; Krapcho, M. SEER Cancer Statistics Review, 1975–2013; National Cancer Institute: Bethesda, MD, 2016.
  4. Mertens, A.C.; Liu, Q.; Neglia, J.P.; Wasilewski, K.; Leisenring, W.; Armstrong, G.T.; Robison, L.L.; Yasui, Y. Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study. J. Natl. Cancer Inst., 2008, 100(19), 1368-1379. doi: 10.1093/jnci/djn310 PMID: 18812549
  5. Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A. Chronic health conditions in adult survivors of childhood cancer. Oncol. Times, 2007, 29(1), 26. doi: 10.1097/01.COT.0000265629.30194.8e
  6. Mulrooney, D.A.; Yeazel, M.W.; Kawashima, T.; Mertens, A.C.; Mitby, P.; Stovall, M.; Donaldson, S.S.; Green, D.M.; Sklar, C.A.; Robison, L.L.; Leisenring, W.M. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ, 2009, 339(1), b4606. doi: 10.1136/bmj.b4606 PMID: 19996459
  7. Armstrong, G.T.; Chen, Y.; Yasui, Y.; Leisenring, W.; Gibson, T.M.; Mertens, A.C.; Stovall, M.; Oeffinger, K.C.; Bhatia, S.; Krull, K.R.; Nathan, P.C.; Neglia, J.P.; Green, D.M.; Hudson, M.M.; Robison, L.L. Reduction in late mortality among 5-year survivors of childhood cancer. N. Engl. J. Med., 2016, 374(9), 833-842. doi: 10.1056/NEJMoa1510795 PMID: 26761625
  8. Gibson, T.M.; Mostoufi-Moab, S.; Stratton, K.L.; Barnea, D.; Chow, E.J.; Donaldson, S.S.; Howell, R.M.; Hudson, M.M.; Leisenring, W.M.; Mahajan, A.; Nathan, P.C.; Ness, K.K.; Sklar, C.A.; Tonorezos, E.S.; Weldon, C.B.; Wells, E.M.; Yasui, Y.; Armstrong, G.T.; Robison, L.L.; Oeffinger, K.C. Temporal patterns in the risk of chronic health conditions among survivors of childhood cancer diagnosed 1970-1999: A report from the childhood cancer survivor study. Lancet Oncol., 2018, 19(12), 1590-1601.
  9. Mulrooney, D.A.; Armstrong, G.T.; Huang, S.; Ness, K.K.; Ehrhardt, M.J.; Joshi, V.M.; Plana, J.C.; Soliman, E.Z.; Green, D.M.; Srivastava, D.; Santucci, A.; Krasin, M.J.; Robison, L.L.; Hudson, M.M. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy. Ann. Intern. Med., 2016, 164(2), 93-101. doi: 10.7326/M15-0424 PMID: 26747086
  10. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. Circulation, 2009, 119, e391-e479.
  11. Denlinger, C.S.; Sanft, T.; Baker, K.S.; Broderick, G.; Demark-Wahnefried, W.; Friedman, D.L.; Goldman, M.; Hudson, M.; Khakpour, N.; King, A.; Koura, D.; Lally, R.M.; Langbaum, T.S.; McDonough, A.L.; Melisko, M.; Montoya, J.G.; Mooney, K.; Moslehi, J.J.; O'Connor, T.; Overholser, L.; Paskett, E.D.; Peppercorn, J.; Pirl, W.; Rodriguez, M.A.; Ruddy, K.J.; Silverman, P.; Smith, S.; Syrjala, K.L.; Tevaarwerk, A.; Urba, S.G.; Wakabayashi, M.T.; Zee, P.; McMillian, N.R.; Freedman-Cass, D.A. Survivorship, Version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2018, 16(10), 1216-1247. doi: 10.6004/jnccn.2018.0078 PMID: 30323092
  12. Lipshultz, S.E.; Adams, M.J.; Colan, S.D.; Constine, L.S.; Herman, E.H.; Hsu, D.T.; Hudson, M.M.; Kremer, L.C.; Landy, D.C.; Miller, T.L.; Oeffinger, K.C.; Rosenthal, D.N.; Sable, C.A.; Sallan, S.E.; Singh, G.K.; Steinberger, J.; Cochran, T.R.; Wilkinson, J.D. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation, 2013, 128(17), 1927-1995. doi: 10.1161/CIR.0b013e3182a88099 PMID: 24081971
  13. Ryan, T.D.; Nagarajan, R.; Godown, J. Cardiovascular toxicities in pediatric cancer survivors. Cardiol. Clin., 2019, 37(4), 533-544. doi: 10.1016/j.ccl.2019.07.002 PMID: 31587793
  14. Moslehi, J.J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med., 2016, 375(15), 1457-1467. doi: 10.1056/NEJMra1100265 PMID: 27732808
  15. Neilan, T.G.; Rothenberg, M.L.; Amiri-Kordestani, L.; Sullivan, R.J.; Steingart, R.M.; Gregory, W.; Hariharan, S.; Hammad, T.A.; Lindenfeld, J.; Murphy, M.J.; Moslehi, J.J. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist, 2018, 23(8), 874-878. doi: 10.1634/theoncologist.2018-0157 PMID: 29802220
  16. Kantarjian, H.M.; DeAngelo, D.J.; Stelljes, M.; Martinelli, G.; Liedtke, M.; Stock, W.; Gökbuget, N.; O'Brien, S.; Wang, K.; Wang, T.; Paccagnella, M.L.; Sleight, B.; Vandendries, E.; Advani, A.S. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med., 2016, 375(8), 740-753. doi: 10.1056/NEJMoa1509277 PMID: 27292104
  17. Available from: https://ec.europa.eu/health/documents/communityregister/2017/20170629138094/anx_138094_el.pdf
  18. Pennesi, E.; Michels, N.; Brivio, E.; van der Velden, V.H.J.; Jiang, Y.; Thano, A.; Ammerlaan, A.J.C.; Boer, J.M.; Beverloo, H.B.; Sleight, B.; Chen, Y.; Vormoor-Bürger, B.; Rives, S.; Bielorai, B.; Rössig, C.; Petit, A.; Rizzari, C.; Engstler, G.; Starý, J.; Bautista Sirvent, F.J.; Chen-Santel, C.; Bruno, B.; Bertrand, Y.; Rialland, F.; Plat, G.; Reinhardt, D.; Vinti, L.; Von Stackelberg, A.; Locatelli, F.; Zwaan, C.M. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: Results from a phase II trial. Leukemia, 2022, 36(6), 1516-1524. doi: 10.1038/s41375-022-01576-3 PMID: 35468945
  19. O'Brien, M.M.; Ji, L.; Shah, N.N.; Rheingold, S.R.; Bhojwani, D.; Yuan, C.M.; Xu, X.; Yi, J.S.; Harris, A.C.; Brown, P.A.; Borowitz, M.J.; Militano, O.; Kairalla, J.; Devidas, M.; Raetz, E.A.; Gore, L.; Loh, M.L.; Phase, I.I.; Phase, I.I. Trial of Inotuzumab Ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's oncology group protocol AALL1621. J. Clin. Oncol., 2022, 40(9), 956-967. doi: 10.1200/JCO.21.01693 PMID: 35007127
  20. Giudice, V.; Vecchione, C.; Selleri, C. Cardiotoxicity of novel targeted hematological therapies. Life, 2020, 10(12), 344. doi: 10.3390/life10120344 PMID: 33322351
  21. Silva, P.N.; Valente, P.M.S.; Castilho, S.R. Monoclonal-induced cardiotoxicity in patients with non-Hodgkin's lymphoma and breast cancer: A retrospective study in an oncology clinic. J. Oncol. Pharm. Pract., 2022. doi: 10.1177/10781552221098426 PMID: 35542978
  22. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera
  23. McAtee, C.L.; Lubega, J.; Underbrink, K.; Curry, K.; Msaouel, P.; Barrow, M.; Muscal, E.; Lotze, T.; Srivaths, P.; Forbes, L.R.; Allen, C.; Bernhardt, M.B. Association of Rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw. Open, 2021, 4(2), e2036321. doi: 10.1001/jamanetworkopen.2020.36321 PMID: 33533931
  24. Darvishi, B.; Farahmand, L.; Jalili, N.; Majidzadeh-A, K. Blinatumomab provoked fatal heart failure. Int. Immunopharmacol., 2016, 41, 42-46. doi: 10.1016/j.intimp.2016.10.017 PMID: 27816725
  25. Mahadeo, K.M.; Khazal, S.J.; Abdel-Azim, H.; Fitzgerald, J.C.; Taraseviciute, A.; Bollard, C.M.; Tewari, P.; Duncan, C.; Traube, C.; McCall, D.; Steiner, M.E.; Cheifetz, I.M.; Lehmann, L.E.; Mejia, R.; Slopis, J.M.; Bajwa, R.; Kebriaei, P.; Martin, P.L.; Moffet, J.; McArthur, J.; Petropoulos, D.; O'Hanlon Curry, J.; Featherston, S.; Foglesong, J.; Shoberu, B.; Gulbis, A.; Mireles, M.E.; Hafemeister, L.; Nguyen, C.; Kapoor, N.; Rezvani, K.; Neelapu, S.S.; Shpall, E.J. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol., 2019, 16(1), 45-63. doi: 10.1038/s41571-018-0075-2 PMID: 30082906
  26. Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.; Milone, M.C.; Levine, B.L.; June, C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 2013, 368(16), 1509-1518. doi: 10.1056/NEJMoa1215134 PMID: 23527958
  27. Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; Mahnke, Y.D.; Melenhorst, J.J.; Rheingold, S.R.; Shen, A.; Teachey, D.T.; Levine, B.L.; June, C.H.; Porter, D.L.; Grupp, S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, 371(16), 1507-1517. doi: 10.1056/NEJMoa1407222 PMID: 25317870
  28. June, C.H.; Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med., 2018, 379(1), 64-73. doi: 10.1056/NEJMra1706169 PMID: 29972754
  29. Chen, Z.I.; Ai, D.I. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol., 2016, 4(5), 675-681. doi: 10.3892/mco.2016.800 PMID: 27123262
  30. Wang, J.; Mou, N.; Yang, Z.; Li, Q.; Jiang, Y.; Meng, J.; Liu, X.; Deng, Q. Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia Br. J. Haematol., 2020, 191(2), 212-222. doi: 10.1111/bjh.16623 PMID: 32232846
  31. Ganatra, S.; Parikh, R.; Neilan, T.G. Cardiotoxicity of immune therapy. Cardiol. Clin., 2019, 37(4), 385-397. doi: 10.1016/j.ccl.2019.07.008 PMID: 31587780
  32. Pathan, N.; Hemingway, C.A.; Alizadeh, A.A.; Stephens, A.C.; Boldrick, J.C.; Oragui, E.E.; McCabe, C.; Welch, S.B.; Whitney, A.; O'Gara, P.; Nadel, S.; Relman, D.A.; Harding, S.E.; Levin, M. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet, 2004, 363(9404), 203-209. doi: 10.1016/S0140-6736(03)15326-3 PMID: 14738793
  33. Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; Go, W.Y.; Eldjerou, L.; Gardner, R.A.; Frey, N.; Curran, K.J.; Peggs, K.; Pasquini, M.; DiPersio, J.F.; van den Brink, M.R.M.; Komanduri, K.V.; Grupp, S.A.; Neelapu, S.S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant., 2019, 25(4), 625-638. doi: 10.1016/j.bbmt.2018.12.758 PMID: 30592986
  34. Alvi, R.M.; Frigault, M.J.; Fradley, M.G.; Jain, M.D.; Mahmood, S.S.; Awadalla, M.; Lee, D.H.; Zlotoff, D.A.; Zhang, L.; Drobni, Z.D.; Hassan, M.Z.O.; Bassily, E.; Rhea, I.; Ismail-Khan, R.; Mulligan, C.P.; Banerji, D.; Lazaryan, A.; Shah, B.D.; Rokicki, A.; Raje, N.; Chavez, J.C.; Abramson, J.; Locke, F.L.; Neilan, T.G. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J. Am. Coll. Cardiol., 2019, 74(25), 3099-3108. doi: 10.1016/j.jacc.2019.10.038 PMID: 31856966
  35. Lefebvre, B.; Kang, Y.; Smith, A.M.; Frey, N.V.; Carver, J.R.; Scherrer-Crosbie, M. Cardiovascular effects of CAR T-cell therapy. JACC: CardioOncology, 2020, 2(2), 193-203. doi: 10.1016/j.jaccao.2020.04.012 PMID: 32776016
  36. Shalabi, H.; Sachdev, V.; Kulshreshtha, A.; Cohen, J.W.; Yates, B.; Rosing, D.R.; Sidenko, S.; Delbrook, C.; Mackall, C.; Wiley, B.; Lee, D.W.; Shah, N.N. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J. Immunother. Cancer, 2020, 8(2), e001159. doi: 10.1136/jitc-2020-001159 PMID: 32883871
  37. Burstein, D.S.; Maude, S.; Grupp, S.; Griffis, H.; Rossano, J.; Lin, K. Cardiac profile of chimeric antigen receptor T-cell therapy in children: A single-institution experience. Biol. Blood Marrow Transplant., 2018, 24(8), 1590-1595. doi: 10.1016/j.bbmt.2018.05.014 PMID: 29772353
  38. Fitzgerald, J.C.; Weiss, S.L.; Maude, S.L.; Barrett, D.M.; Lacey, S.F.; Melenhorst, J.J.; Shaw, P.; Berg, R.A.; June, C.H.; Porter, D.L.; Frey, N.V.; Grupp, S.A.; Teachey, D.T. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med., 2017, 45(2), e124-e131. doi: 10.1097/CCM.0000000000002053 PMID: 27632680
  39. Kochenderfer, J.N.; Somerville, R.P.T.; Lu, T.; Shi, V.; Bot, A.; Rossi, J.; Xue, A.; Goff, S.L.; Yang, J.C.; Sherry, R.M.; Klebanoff, C.A.; Kammula, U.S.; Sherman, M.; Perez, A.; Yuan, C.M.; Feldman, T.; Friedberg, J.W.; Roschewski, M.J.; Feldman, S.A.; McIntyre, L.; Toomey, M.A.; Rosenberg, S.A. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T-cells are associated with high serum Interleukin-15 levels. J. Clin. Oncol., 2017, 35(16), 1803-1813. doi: 10.1200/JCO.2016.71.3024 PMID: 28291388
  40. Wang, S.Y.; Zhao, L.N.; Cheng, H.; Shi, M.; Chen, W.; Qi, K.M.; Sun, C.; Wang, X.; Cao, J.; Xu, K.L. Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi, 2022, 43(7), 557-561. PMID: 36709132
  41. Lee, D.W.; Kochenderfer, J.N.; Stetler-Stevenson, M.; Cui, Y.K.; Delbrook, C.; Feldman, S.A.; Fry, T.J.; Orentas, R.; Sabatino, M.; Shah, N.N.; Steinberg, S.M.; Stroncek, D.; Tschernia, N.; Yuan, C.; Zhang, H.; Zhang, L.; Rosenberg, S.A.; Wayne, A.S.; Mackall, C.L. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 2015, 385(9967), 517-528. doi: 10.1016/S0140-6736(14)61403-3 PMID: 25319501
  42. Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; Qu, J.; Wasielewska, T.; He, Q.; Fink, M.; Shinglot, H.; Youssif, M.; Satter, M.; Wang, Y.; Hosey, J.; Quintanilla, H.; Halton, E.; Bernal, Y.; Bouhassira, D.C.G.; Arcila, M.E.; Gonen, M.; Roboz, G.J.; Maslak, P.; Douer, D.; Frattini, M.G.; Giralt, S.; Sadelain, M.; Brentjens, R. Efficacy and toxicity management of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Sci. Transl. Med., 2014, 6(224), 224ra25. doi: 10.1126/scitranslmed.3008226 PMID: 24553386
  43. Yáñez, L.; Sánchez-Escamilla, M.; Perales, M.A. CAR T-cell toxicity: Current management and future directions. HemaSphere, 2019, 3(2), e186. doi: 10.1097/HS9.0000000000000186 PMID: 31723825
  44. Kymriah-Epar-Product-Information. Available from: https://www.ema.europa.eu/documents/product-information/kymriah- epar-product-information_en.pdf
  45. Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Magenau, J.M.; Holte, H.; Pantano, S.; Pacaud, L.B.; Awasthi, R.; Chu, J.; Anak, Ö.; Salles, G.; Maziarz, R.T. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med., 2019, 380(1), 45-56. doi: 10.1056/NEJMoa1804980 PMID: 30501490
  46. Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; Qayed, M.; De Moerloose, B.; Hiramatsu, H.; Schlis, K.; Davis, K.L.; Martin, P.L.; Nemecek, E.R.; Yanik, G.A.; Peters, C.; Baruchel, A.; Boissel, N.; Mechinaud, F.; Balduzzi, A.; Krueger, J.; June, C.H.; Levine, B.L.; Wood, P.; Taran, T.; Leung, M.; Mueller, K.T.; Zhang, Y.; Sen, K.; Lebwohl, D.; Pulsipher, M.A.; Grupp, S.A. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med., 2018, 378(5), 439-448. doi: 10.1056/NEJMoa1709866 PMID: 29385370
  47. Laetsch, T.W.; Myers, G.D.; Baruchel, A.; Dietz, A.C.; Pulsipher, M.A.; Bittencourt, H.; Buechner, J.; De Moerloose, B.; Davis, K.L.; Nemecek, E.; Driscoll, T.; Mechinaud, F.; Boissel, N.; Rives, S.; Bader, P.; Peters, C.; Sabnis, H.S.; Grupp, S.A.; Yanik, G.A.; Hiramatsu, H.; Stefanski, H.E.; Rasouliyan, L.; Yi, L.; Shah, S.; Zhang, J.; Harris, A.C. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial. Lancet Oncol., 2019, 20(12), 1710-1718. doi: 10.1016/S1470-2045(19)30493-0 PMID: 31606419
  48. Kerr, W.G.; Chisholm, J.D. The next generation of immunotherapy for cancer: Small molecules could make big waves. J. Immunol., 2019, 202(1), 11-19. doi: 10.4049/jimmunol.1800991 PMID: 30587569
  49. Kabir, T.F.; Chauhan, A.; Anthony, L.; Hildebrandt, G.C. Immune checkpoint inhibitors in pediatric solid tumors: Status in 2018. Ochsner J., 2018, 18(4), 370-376. doi: 10.31486/toj.18.0055 PMID: 30559623
  50. Bosse, K.R.; Majzner, R.G.; Mackall, C.L.; Maris, J.M. Immune-based approaches for the treatment of pediatric malignancies. Annu. Rev. Cancer Biol., 2020, 4(1), 353-370. doi: 10.1146/annurev-cancerbio-030419-033436 PMID: 34113750
  51. Love, V.A.; Grabie, N.; Duramad, P.; Stavrakis, G.; Sharpe, A.; Lichtman, A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ. Res., 2007, 101(3), 248-257. doi: 10.1161/CIRCRESAHA.106.147124 PMID: 17569889
  52. Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; Honjo, T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 2001, 291(5502), 319-322. doi: 10.1126/science.291.5502.319 PMID: 11209085
  53. Rubio-Infante, N.; Ramírez-Flores, Y.A.; Castillo, E.C.; Lozano, O.; García-Rivas, G.; Torre-Amione, G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta‐analysis. Eur. J. Heart Fail., 2021, 23(10), 1739-1747. doi: 10.1002/ejhf.2289 PMID: 34196077
  54. Salem, J.E.; Manouchehri, A.; Moey, M.; Lebrun-Vignes, B.; Bastarache, L.; Pariente, A.; Gobert, A.; Spano, J.P.; Balko, J.M.; Bonaca, M.P.; Roden, D.M.; Johnson, D.B.; Moslehi, J.J. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol., 2018, 19(12), 1579-1589. doi: 10.1016/S1470-2045(18)30608-9 PMID: 30442497
  55. Li, C.; Bhatti, S.A.; Ying, J. Immune checkpoint inhibitors—associated cardiotoxicity. Cancers, 2022, 14(5), 1145. doi: 10.3390/cancers14051145 PMID: 35267453
  56. Hu, J.; Tian, R.; Ma, Y.; Zhen, H.; Ma, X.; Su, Q.; Cao, B. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis. Front. Oncol., 2021, 11, 645245. doi: 10.3389/fonc.2021.645245 PMID: 34123795
  57. Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353(2), 172-187. doi: 10.1056/NEJMra044389 PMID: 16014887
  58. Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B.; Goldman, J.; O'Brien, S.G.; Russell, N.; Fischer, T.; Ottmann, O.; Cony-Makhoul, P.; Facon, T.; Stone, R.; Miller, C.; Tallman, M.; Brown, R.; Schuster, M.; Loughran, T.; Gratwohl, A.; Mandelli, F.; Saglio, G.; Lazzarino, M.; Russo, D.; Baccarani, M.; Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 2002, 346(9), 645-652. doi: 10.1056/NEJMoa011573 PMID: 11870241
  59. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037. doi: 10.1056/NEJM200104053441401 PMID: 11287972
  60. Druker, B.J.; Guilhot, F.; O'Brien, S.G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.W.N.; Silver, R.T.; Goldman, J.M.; Stone, R.M.; Cervantes, F.; Hochhaus, A.; Powell, B.L.; Gabrilove, J.L.; Rousselot, P.; Reiffers, J.; Cornelissen, J.J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J.L.; Radich, J.P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 2006, 355(23), 2408-2417. doi: 10.1056/NEJMoa062867 PMID: 17151364
  61. Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Harris, D.M.; Ismail, N.S.; Chen, J-H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H.; Morgan, J.A. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370(9604), 2011-2019. doi: 10.1016/S0140-6736(07)61865-0 PMID: 18083403
  62. Ewer, M.S.; Suter, T.M.; Lenihan, D.J.; Niculescu, L.; Breazna, A.; Demetri, G.D.; Motzer, R.J. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer, 2014, 50(12), 2162-2170. doi: 10.1016/j.ejca.2014.05.013 PMID: 24930624
  63. Jain, D.; Russell, R.R.; Schwartz, R.G.; Panjrath, G.S.; Aronow, W. Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. Curr. Cardiol. Rep., 2017, 19(5), 36. doi: 10.1007/s11886-017-0846-x PMID: 28374177
  64. Chaar, M.; Kamta, J.; Ait-Oudhia, S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets Ther., 2018, 11, 6227-6237. doi: 10.2147/OTT.S170138 PMID: 30288058
  65. Motokawa, T.; Ikeda, S.; Ueno, Y.; Eguchi, M.; Minami, T.; Kawano, H.; Kobayashi, K.; Imaizumi, Y.; Maemura, K. Comparison of Dasatinib- and Imatinib-related cardiotoxic adverse events in Japanese patients with chronic myeloid leukemia and gastrointestinal stromal tumor. Circ. Rep., 2022, 4(1), CR-21-CR-0140. doi: 10.1253/circrep.CR-21-0140 PMID: 35083382
  66. Casavecchia, G.; Spinosa, G.; De Gennaro, L.; Zicchino, S.; Gravina, M.; Magnesa, M.; Di Biase, M.; Brunetti, N.D. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Acta Cardiol., 2022, 77(2), 130-135. doi: 10.1080/00015385.2021.1888017 PMID: 33685352
  67. Narayan, H.K.; Sheline, K.; Wong, V.; Kuo, D.; Choo, S.; Yoon, J.; Leger, K.; Kutty, S.; Fradley, M.; Tremoulet, A.; Ky, B.; Armenian, S.; Guha, A. Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration. Pediatr. Blood Cancer, 2023, 70(2), e30059. doi: 10.1002/pbc.30059 PMID: 36385736

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2023